Back to Search

Izalontamab vs Platinum-Pemetrexed for Lung Cancer

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Recruiting Phase 2 Phase 3 Interventional Study
Non-Small Cell Lung Cancer
More trials: Cancer clinical trials· Cancer trials in California
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
500 (estimated)
Sponsor
Bristol-Myers Squibb · Industry
Who this trial is looking for

This trial is looking for patients with a specific type of lung cancer that has not responded to previous treatment. Participants will receive either Izalontamab Brengitecan or a combination of platinum-based chemotherapy and pemetrexed.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have non-squamous non-small cell lung cancer.
  • I have a documented EGFR mutation.
  • My cancer has worsened after treatment with a 3rd-generation EGFR TKI.
  • I can receive platinum-based chemotherapy.

You may not be able to join if

  • I have inadequate organ function or bone marrow issues.
  • I have leptomeningeal metastases or spinal cord compression.
  • I have poorly controlled medical conditions.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Non-squamous NSCLC, not amenable to treatment in curative intent. * Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation). * Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination thera…
Contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286

Clinical.Trials@bms.com

CONTACT

First line of the email MUST contain NCT # and Site #.

CONTACT

NCT ID: NCT07100080 Source: ClinicalTrials.gov